Fewer Complications Seen With Vitamin C, D Supplementation in AML
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Sept. 6, 2023 -- For patients with acute myeloid leukemia (AML), supplementation with vitamins C and D during chemotherapy may improve outcomes but may not improve overall survival (OS), according to a study published online Sept. 6 in Blood Advances.
Pierre Luc Mouchel, M.D., from the Centre Hospitalier Universitaire de Toulouse in France, and colleagues compared the outcomes of patients treated before and after the practice change of adding vitamins C and D to the supportive care of AML patients in 2018. A total of 431 patients were included from 2015 to 2020: 262 and 169 received no supplementation and supplementation, respectively. Vitamins C and D were administered from day 10 of chemotherapy until hematologic recovery from induction and consolidation.
The researchers found that in the supplementation group, vitamin D levels increased significantly upon recovery from induction compared with diagnosis, and pretransplant levels were significantly higher in the supplementation group versus the control group (median, 33 versus 19 ng/mL). The rates of bacterial or fungal infection, hemorrhage, or macrophage activation syndrome were lower in the supplementation group during induction, while no difference was seen in response rate, relapse incidence, or OS. There was a significant interaction between vitamin C/D and NPM1 mutation in a multivariate analysis for OS, indicating better OS with supplementation among patients with NPM1 mutations (hazard ratio [HR], 0.52; 95 percent confidence interval [CI], 0.30 to 0.90) versus wild-type NPM1 patients (HR, 1.01; 95 percent CI, 0.68 to 1.51).
"We have shown that supplementation is feasible and safe and may help reduce some significant adverse events associated with intensive chemotherapy, which is a clear benefit for patients," coauthor Christian Récher, M.D., of the University Cancer Institute of Toulouse, said in a statement.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Posttransplant Cyclophosphamide GVHD Prophylaxis Beneficial in Leukemia
MONDAY, June 24, 2024 -- For patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation, posttransplant cyclophosphamide (PTCy)...
ASCO: Asciminib Has Superior Efficacy to TKIs for Newly Diagnosed Leukemia
WEDNESDAY, June 5, 2024 -- For patients with newly diagnosed chronic myeloid leukemia (CML), asciminib shows superior efficacy and a favorable safety profile compared with...
Oldest Adults With Acute Myeloid Leukemia Benefit From Venetoclax
THURSDAY, May 16, 2024 -- For older adults with acute myeloid leukemia (AML), venetoclax (VEN) combined with a hypomethylating agent (HMA) is safe and effective and can prolong...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.